Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $405.57
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 19, 26 |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 16, 26 | Sheena Jonathan | director, other: CO-FOUNDER | S-Sale | 142 @ $398.95 | $56.65K |
| Canaccord Genuity |
| maintain |
| Buy |
| Buy |
| Oct 14, 26 | JP Morgan | maintain | Overweight | Overweight |
| Oct 13, 26 | TD Cowen | maintain | Buy | Buy |
| Oct 13, 26 | Morgan Stanley | maintain | Overweight | Overweight |
| Oct 7, 26 | Barclays | maintain | Overweight | Overweight |
| Oct 6, 26 | Citigroup | maintain | Buy | Buy |
| Oct 1, 26 | Guggenheim | maintain | Buy | Buy |
| Sep 25, 26 | RBC Capital | maintain | Outperform | Outperform |
| Sep 9, 26 | UBS | maintain | Buy | Buy |
| Oct 16, 26 |
| Sheena Jonathan |
| director, other: CO-FOUNDER |
| S-Sale |
| 215 @ $399.34 |
| $85.86K |
| Oct 16, 26 | Sheena Jonathan | director, other: CO-FOUNDER | S-Sale | 280 @ $400.68 | $112.2K |
| Oct 16, 26 | Sheena Jonathan | director, other: CO-FOUNDER | S-Sale | 60 @ $401.62 | $24.10K |
| Oct 16, 26 | Sheena Jonathan | director, other: CO-FOUNDER | S-Sale | 280 @ $401.29 | $112.4K |
| Oct 16, 26 | Sheena Jonathan | director, other: CO-FOUNDER | S-Sale | 90 @ $403.70 | $36.33K |
| Oct 16, 26 | Sheena Jonathan | director, other: CO-FOUNDER | S-Sale | 90 @ $404.25 | $36.38K |
| Oct 16, 26 | Sheena Jonathan | director, other: CO-FOUNDER | S-Sale | 50 @ $405.15 | $20.26K |
Stock news · updated daily
A wild Thursday saw Treasury yields crater, oil surge past $111, crypto liquidations top $431 million, and Meta's cash flow surprise rattle markets. Now analysts are reshuffling their calls on some of the week's most closely watched names.
Both of these ETFs look the part, but only one is truly the better buy for investors.
NTRA partners with TransCode Therapeutics to use Signatera MRD testing in a Phase 2a colorectal cancer trial, aiming to accelerate enrollment and research.
SteelPeak Wealth LLC grew its position in Natera, Inc. (NASDAQ: NTRA) by 81.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,767 shares of the medical research company's stock after acquiring an additional 2,138 shares during the quarter.
[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology wi
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 23–26 in Madrid, Spain.New evidence highlights the power of Natera's latest ultrasensitive molecular residual disease (MRD) technology, Signatera Genome with Phased and Structural Variants, which has demonstrat.
Natera shares consolidate after a 76% rally, holding key moving-average support as traders watch for a breakout above $437.41 to extend the bullish trend.
[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -0.49 | -0.47 | Beat 4.8% | $752.8M |
| May 7, 2026 | -0.54 | -0.56 | Miss -3.3% | $696.6M |
| Feb 26, 2026 | -0.51 | 0.35 | Beat 168.4% | $665.5M |
| Nov 6, 2025 | -0.39 | -0.64 | Miss -65.9% | $592.2M |
| Aug 7, 2025 | -0.62 | -0.74 | Miss -20.2% | $546.6M |
| May 8, 2025 | -0.64 | -0.50 | Beat 21.9% | $501.8M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 20, 2026 | 2026-10-20 21:35:06 | View |
| 4 | Oct 16, 2026 | 2026-10-16 21:35:08 | View |
| 4 | Oct 9, 2026 | 2026-10-09 21:25:05 | View |
| 4 | Oct 2, 2026 | 2026-10-02 21:35:07 | View |
| 4 | Oct 2, 2026 | 2026-10-02 21:35:06 | View |
| 4 | Sep 25, 2026 | 2026-09-25 21:35:06 | View |
| 144 | Sep 23, 2026 | 2026-09-23 10:58:04 | View |
| 4 | Sep 18, 2026 | 2026-09-18 21:35:06 | View |
| 4 | Sep 17, 2026 | 2026-09-17 21:35:07 | View |
| 4 | Sep 16, 2026 | 2026-09-16 21:35:07 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | NTRA | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -298.2x | -59.2x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -280.0x | EPS est. -1.45 | In line |
| Price / Book | 31.9x | 12.6x | Elevated |
| Price / Sales | 21.6x | 10.0x | Elevated |
| EV / EBITDA | -322.4x | -62.2x | Elevated |
| Return on equity | -11.7% | — | Weak |
| Gross margin | 65.3% | 52.8% | Above hist. |
| Debt / Equity | 0.13 | 0.42 | Conservative |
| Piotroski / Altman Z | 3/9 | Z 41.19 | Safe zone |
Discounted cash flow model
1255 daily bars · split adjusted
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 57.99 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 46.35 | Oscillator | Neutral |
| Williams %R (14) | -55.59 | Oscillator | Neutral |
| MACD (12, 26, 9) | 10.14 (Hist -2.50) | Oscillator | Sell |
| Average Directional Index (14) | 35.88 (+DI 20.2 / -DI 18.4) | Trend | Strong Buy |
| EMA 20 | 397.18 | MA | Buy |
| SMA 20 | 404.20 | MA | Buy |
| EMA 50 | 368.00 | MA | Strong Buy |
| SMA 50 | 367.00 | MA | Strong Buy |
| SMA 200 | 261.63 | MA | Strong Buy |